Iovance Biotherapeutics Net Worth
Iovance Biotherapeutics Net Worth Breakdown | IOVA |
Iovance Biotherapeutics Net Worth Analysis
Iovance Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Iovance Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Iovance Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Iovance Biotherapeutics' net worth analysis. One common approach is to calculate Iovance Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Iovance Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Iovance Biotherapeutics' net worth. This approach calculates the present value of Iovance Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Iovance Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Iovance Biotherapeutics' net worth. This involves comparing Iovance Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Iovance Biotherapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Iovance Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Iovance Biotherapeutics' net worth research are outlined below:
| Iovance Biotherapeutics generated a negative expected return over the last 90 days | |
| Iovance Biotherapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 164.07 M. Net Loss for the year was (372.18 M) with profit before overhead, payroll, taxes, and interest of 40.08 M. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash with (352.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: 11,400 Shares in Iovance Biotherapeutics, Inc. Purchased by Kazazian Asset Management LLC |
Iovance Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Iovance Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Iovance Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Iovance Biotherapeutics Target Price Consensus
Iovance target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Iovance Biotherapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most Iovance analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Iovance stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Iovance Biotherapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIovance Biotherapeutics Target Price Projection
Iovance Biotherapeutics' current and average target prices are 3.54 and 23.77, respectively. The current price of Iovance Biotherapeutics is the price at which Iovance Biotherapeutics is currently trading. On the other hand, Iovance Biotherapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Iovance Biotherapeutics Market Quote on 23rd of March 2025
Target Price
Analyst Consensus On Iovance Biotherapeutics Target Price
Know Iovance Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Iovance Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Iovance Biotherapeutics backward and forwards among themselves. Iovance Biotherapeutics' institutional investor refers to the entity that pools money to purchase Iovance Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Artisan Partners Limited Partnership | 2024-12-31 | 4.5 M | Goldman Sachs Group Inc | 2024-12-31 | 4.1 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4 M | Principal Financial Group Inc | 2024-12-31 | 3.6 M | Venbio Select Advisor Llc | 2024-12-31 | 3.5 M | Palo Alto Investors, Llc | 2024-12-31 | 3 M | Balyasny Asset Management Llc | 2024-12-31 | 2.8 M | Ubs Group Ag | 2024-12-31 | 2.7 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 2.7 M | Vanguard Group Inc | 2024-12-31 | 27.5 M | Mhr Fund Management Llc | 2024-12-31 | 24.4 M |
Follow Iovance Biotherapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.16 B.Market Cap |
|
Project Iovance Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.52) | (0.55) |
When accessing Iovance Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Iovance Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Iovance Biotherapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Iovance Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iovance Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Iovance Biotherapeutics' management manipulating its earnings.
Evaluate Iovance Biotherapeutics' management efficiency
Iovance Biotherapeutics has return on total asset (ROA) of (0.2922) % which means that it has lost $0.2922 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5748) %, meaning that it created substantial loss on money invested by shareholders. Iovance Biotherapeutics' management efficiency ratios could be used to measure how well Iovance Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.53. At present, Iovance Biotherapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 476.1 M, whereas Total Current Assets are forecasted to decline to about 235.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.45 | 2.57 | |
| Tangible Book Value Per Share | 1.48 | 1.55 | |
| Enterprise Value Over EBITDA | (5.28) | (5.54) | |
| Price Book Value Ratio | 3.02 | 2.87 | |
| Enterprise Value Multiple | (5.28) | (5.54) | |
| Price Fair Value | 3.02 | 2.87 | |
| Enterprise Value | 1.7 B | 1.8 B |
The leadership approach at Iovance Biotherapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 5.446 | Revenue | Quarterly Revenue Growth 151.892 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Iovance Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Iovance Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Iovance Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Iovance Biotherapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 12th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Iovance Biotherapeutics Earnings Estimation Breakdown
The calculation of Iovance Biotherapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Iovance Biotherapeutics is estimated to be -0.42 with the future projection ranging from a low of -0.26 to a high of -0.22. Please be aware that this consensus of annual earnings estimates for Iovance Biotherapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.26 Lowest | Expected EPS | -0.22 Highest |
Iovance Biotherapeutics Earnings Projection Consensus
Suppose the current estimates of Iovance Biotherapeutics' value are higher than the current market price of the Iovance Biotherapeutics stock. In this case, investors may conclude that Iovance Biotherapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Iovance Biotherapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 14 | 84.68% | -0.26 | -0.42 | -1.28 |
Iovance Biotherapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Iovance Biotherapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Iovance Biotherapeutics predict the company's earnings will be in the future. The higher the earnings per share of Iovance Biotherapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Iovance Biotherapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Iovance Biotherapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Iovance Biotherapeutics should always be considered in relation to other companies to make a more educated investment decision.Iovance Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Iovance Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.2676 | -0.26 | 0.0076 | 2 | ||
2024-11-07 | 2024-09-30 | -0.3 | -0.28 | 0.02 | 6 | ||
2024-08-08 | 2024-06-30 | -0.35 | -0.34 | 0.01 | 2 | ||
2024-05-09 | 2024-03-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2024-02-28 | 2023-12-31 | -0.43 | -0.45 | -0.02 | 4 | ||
2023-11-07 | 2023-09-30 | -0.45 | -0.46 | -0.01 | 2 | ||
2023-08-08 | 2023-06-30 | -0.8 | -0.47 | 0.33 | 41 | ||
2023-05-09 | 2023-03-31 | -0.74 | -0.5 | 0.24 | 32 | ||
2023-02-28 | 2022-12-31 | -0.64 | -0.64 | 0.0 | 0 | ||
2022-11-03 | 2022-09-30 | -0.64 | -0.63 | 0.01 | 1 | ||
2022-08-04 | 2022-06-30 | -0.61 | -0.63 | -0.02 | 3 | ||
2022-05-05 | 2022-03-31 | -0.64 | -0.58 | 0.06 | 9 | ||
2022-02-24 | 2021-12-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2021-11-04 | 2021-09-30 | -0.53 | -0.55 | -0.02 | 3 | ||
2021-08-05 | 2021-06-30 | -0.51 | -0.53 | -0.02 | 3 | ||
2021-05-06 | 2021-03-31 | -0.49 | -0.51 | -0.02 | 4 | ||
2021-02-25 | 2020-12-31 | -0.44 | -0.47 | -0.03 | 6 | ||
2020-11-05 | 2020-09-30 | -0.46 | -0.4 | 0.06 | 13 | ||
2020-08-06 | 2020-06-30 | -0.53 | -0.47 | 0.06 | 11 | ||
2020-05-05 | 2020-03-31 | -0.51 | -0.55 | -0.04 | 7 | ||
2020-02-25 | 2019-12-31 | -0.41 | -0.5 | -0.09 | 21 | ||
2019-11-04 | 2019-09-30 | -0.39 | -0.4 | -0.01 | 2 | ||
2019-08-01 | 2019-06-30 | -0.29 | -0.38 | -0.09 | 31 | ||
2019-05-07 | 2019-03-31 | -0.29 | -0.3 | -0.01 | 3 | ||
2019-02-27 | 2018-12-31 | -0.27 | -0.27 | 0.0 | 0 | ||
2018-11-06 | 2018-09-30 | -0.33 | -0.36 | -0.03 | 9 | ||
2018-08-06 | 2018-06-30 | -0.31 | -0.34 | -0.03 | 9 | ||
2018-05-10 | 2018-03-31 | -0.29 | -0.31 | -0.02 | 6 | ||
2018-03-12 | 2017-12-31 | -0.32 | -0.36 | -0.04 | 12 | ||
2017-10-31 | 2017-09-30 | -0.34 | -0.35 | -0.01 | 2 | ||
2017-08-01 | 2017-06-30 | -0.34 | -0.37 | -0.03 | 8 | ||
2017-05-01 | 2017-03-31 | -0.28 | -0.33 | -0.05 | 17 | ||
2017-03-07 | 2016-12-31 | -0.25 | -0.25 | 0.0 | 0 | ||
2016-11-04 | 2016-09-30 | -0.22 | -0.17 | 0.05 | 22 | ||
2016-08-08 | 2016-06-30 | -0.19 | -0.23 | -0.04 | 21 | ||
2016-05-09 | 2016-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2016-03-10 | 2015-12-31 | -0.2 | -0.2 | 0.0 | 0 | ||
2015-11-05 | 2015-09-30 | -0.16 | -0.16 | 0.0 | 0 | ||
2015-08-10 | 2015-06-30 | -0.15 | -0.14 | 0.01 | 6 | ||
2015-05-11 | 2015-03-31 | -0.11 | -0.14 | -0.03 | 27 | ||
2015-03-16 | 2014-12-31 | -0.09 | -0.18 | -0.09 | 100 | ||
2014-11-13 | 2014-09-30 | -0.13 | -0.11 | 0.02 | 15 | ||
2014-08-08 | 2014-06-30 | -0.12 | -0.09 | 0.03 | 25 | ||
2014-03-28 | 2013-12-31 | -0.11 | -1.5 | -1.39 | 1263 |
Iovance Biotherapeutics Corporate Management
| Friedrich MD | Chief Officer | Profile | |
| Michele PMP | Senior Management | Profile | |
| JeanMarc MBA | Chief Officer | Profile | |
| Sara Pellegrino | Senior Communications | Profile | |
| Madan Jagasia | Ex Affairs | Profile | |
| Tracy Winton | Executive Resources | Profile | |
| Brian MBA | Senior Technology | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 151.892 | Return On Assets | Return On Equity |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.